Related Experiment Video
Updated: May 11, 2026
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
Targeting PPAR isoforms following CNS injury
Heather M Yonutas1, Patrick G Sullivan
1Spinal Cord and Brain Injury Research Center and Department of Anatomy & Neurobiology, University of Kentucky, Lexington, KY 40536-0509, USA.
Abstract:
A major focus has developed for the discovery of proregenerative and neuroprotective therapeutic agents to help the millions of Americans who receive a CNS injury annually. Tribulations have been encountered along the way due to the complicated set of pathways that are initiated post-injury. To target this complicated multifaceted signaling cascade, the most promising therapeutics target multiple pathways involved in the secondary injury cascade, such as neuroinflammation, the generation of ROS and mitochondrial dysfunction. Compelling experimental data demonstrates that mitochondrial dysfunction is a pivotal link in the neuropathological sequelae of brain injury. A group of PPAR agonists, specifically rosiglitazone and pioglitazone, have shown an extreme amount of promise in the realm of drug discovery for CNS injury due to their ability to increase functional recovery and decrease lesion volumes following injury. The therapeutic effects of these PPAR agonists are thought to be a direct result of PPAR activity however new data is arising that shows some of the effects may be independent of PPAR activity, targeting a novel mitochondrial protein called mitoNEET. In this review, a thorough evaluation of the role of PPAR and mitoNEET in rosiglitazone and pioglitazone mediated neuroprotection will be completed in order to shed light on the mechanism of a new possible therapeutic intervention for CNS injury.
Insights
New therapeutic agents targeting central nervous system (CNS) injury show promise. Rosiglitazone and pioglitazone may offer neuroprotection by targeting PPAR or the novel mitoNEET protein, independent of PPAR activity.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Central nervous system (CNS) injuries affect millions annually, necessitating proregenerative and neuroprotective therapies.
- Secondary injury cascades, including neuroinflammation, reactive oxygen species (ROS), and mitochondrial dysfunction, complicate treatment.
- Mitochondrial dysfunction is a critical factor in the neuropathology following brain injury.
Purpose of the Study:
- To evaluate the role of PPAR and mitoNEET in mediating neuroprotection by rosiglitazone and pioglitazone.
- To elucidate the mechanisms underlying the therapeutic effects of these PPAR agonists in CNS injury.
- To explore novel therapeutic interventions for CNS injury targeting mitochondrial proteins.
Main Methods:
- Review of experimental data on PPAR agonists (rosiglitazone, pioglitazone) in CNS injury models.
- Analysis of studies investigating the involvement of PPAR activity in neuroprotection.
- Examination of emerging research on mitoNEET as a potential therapeutic target.
Main Results:
- Rosiglitazone and pioglitazone demonstrate significant promise in enhancing functional recovery and reducing lesion volume post-CNS injury.
- Evidence suggests that the neuroprotective effects of these drugs may be partly independent of PPAR activation.
- The mitochondrial protein mitoNEET is identified as a novel target for the observed therapeutic effects.
Conclusions:
- PPAR agonists show therapeutic potential for CNS injury, with mechanisms potentially involving both PPAR-dependent and PPAR-independent pathways.
- Targeting mitoNEET represents a promising new avenue for developing neuroprotective agents for CNS injuries.
- Further research into the role of mitoNEET could lead to innovative treatments for millions affected by CNS injuries.
